Option Care Health (NASDAQ:OPCH) reported second-quarter results that came in largely inline with revenue expectations while delivering an earnings beat, sending shares higher in pre-market trading.
Q2 Performance: Mixed Revenue, Clear Profitability Beat
For the quarter ended June 30, 2026, OPTION CARE HEALTH INC (NASDAQ:OPCH) posted net revenue of $1.442 billion, a 1.9% increase year-over-year but slightly below the analyst consensus estimate of $1.447 billion. The deviation was less than 1%, placing revenue squarely inline with what the market had modeled.
On the bottom line, the company outperformed. Adjusted diluted earnings per share reached $0.45, up 9.8% from $0.41 a year ago and ahead of the $0.4362 analysts had forecast. GAAP net income rose 6.7% to $53.9 million, while adjusted EBITDA grew 3.0% to $117.5 million.
Key financial highlights included:
- Net revenue: $1,442 million (up 1.9%)
- GAAP net income: $53.9 million (up 6.7%)
- Adjusted diluted EPS: $0.45 (up 9.8%)
- Adjusted EBITDA: $117.5 million (up 3.0%)
- Cash provided by operating activities: $184 million in Q2 alone
- Share repurchases: $150 million in the quarter
Guidance: Solid Top-Line Expectations but Below Street View
Management updated full-year 2026 guidance, projecting net revenue in a range of $5.675 billion to $5.775 billion. The midpoint of $5.725 billion falls short of the analyst consensus of $5.825 billion, suggesting slightly tempered expectations for the back half of the year.
However, the adjusted EBITDA outlook of $480 million to $495 million and adjusted diluted EPS guidance of $1.85 to $1.92 imply continued margin discipline. For the third quarter, the company expects sequential net revenue growth in the low-to-mid single digits and sequential adjusted EBITDA growth in the mid single digits.
CEO John C. Rademacher noted confidence in the company's strategic initiatives and long-term growth trajectory, citing the strength of its clinical platform and market opportunities.
Market Reaction: Pre-Market Gains on Earnings Beat and Cash Flow
Shares of Option Care Health were up approximately 9% in pre-market trading following the release. While revenue was nearly identical to estimates and the full-year revenue guidance came in slightly below consensus, the market appears to be focusing on the EPS beat, robust cash generation ($184 million in operating cash flow in Q2 alone), and the aggressive share repurchase program.
The company bought back $150 million worth of stock during the quarter, signaling confidence from management and providing a floor for investor sentiment. The strong operating cash flow also supports its ability to continue returning capital while investing in growth.
Considerations and Risks
Investors should note that the modest revenue growth rate of 1.9% reflects a relatively mature market for home infusion services, and the full-year revenue guidance implies a deceleration from the first-half run rate. Reimbursement dynamics and payer relationships remain key variables. The company carries long-term debt of $1.15 billion, though operating cash flow comfortably covers interest and capital needs.
For additional historical earnings data, readers can review the detailed quarterly results page. To track future projections and consensus estimates, the analyst forecast page provides forward-looking expectations.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Option Care Health (NASDAQ:OPCH) Beats Q2 Earnings Estimates, Shares Rise on Strong Cash Flow and Buybacks
Option Care Health (NASDAQ:OPCH) reported second-quarter results that came in largely inline with revenue expectations while delivering an earnings beat, sending shares higher in pre-market trading.
Q2 Performance: Mixed Revenue, Clear Profitability Beat
For the quarter ended June 30, 2026, OPTION CARE HEALTH INC (NASDAQ:OPCH) posted net revenue of $1.442 billion, a 1.9% increase year-over-year but slightly below the analyst consensus estimate of $1.447 billion. The deviation was less than 1%, placing revenue squarely inline with what the market had modeled.
On the bottom line, the company outperformed. Adjusted diluted earnings per share reached $0.45, up 9.8% from $0.41 a year ago and ahead of the $0.4362 analysts had forecast. GAAP net income rose 6.7% to $53.9 million, while adjusted EBITDA grew 3.0% to $117.5 million.
Key financial highlights included:
Guidance: Solid Top-Line Expectations but Below Street View
Management updated full-year 2026 guidance, projecting net revenue in a range of $5.675 billion to $5.775 billion. The midpoint of $5.725 billion falls short of the analyst consensus of $5.825 billion, suggesting slightly tempered expectations for the back half of the year.
However, the adjusted EBITDA outlook of $480 million to $495 million and adjusted diluted EPS guidance of $1.85 to $1.92 imply continued margin discipline. For the third quarter, the company expects sequential net revenue growth in the low-to-mid single digits and sequential adjusted EBITDA growth in the mid single digits.
CEO John C. Rademacher noted confidence in the company's strategic initiatives and long-term growth trajectory, citing the strength of its clinical platform and market opportunities.
Market Reaction: Pre-Market Gains on Earnings Beat and Cash Flow
Shares of Option Care Health were up approximately 9% in pre-market trading following the release. While revenue was nearly identical to estimates and the full-year revenue guidance came in slightly below consensus, the market appears to be focusing on the EPS beat, robust cash generation ($184 million in operating cash flow in Q2 alone), and the aggressive share repurchase program.
The company bought back $150 million worth of stock during the quarter, signaling confidence from management and providing a floor for investor sentiment. The strong operating cash flow also supports its ability to continue returning capital while investing in growth.
Considerations and Risks
Investors should note that the modest revenue growth rate of 1.9% reflects a relatively mature market for home infusion services, and the full-year revenue guidance implies a deceleration from the first-half run rate. Reimbursement dynamics and payer relationships remain key variables. The company carries long-term debt of $1.15 billion, though operating cash flow comfortably covers interest and capital needs.
For additional historical earnings data, readers can review the detailed quarterly results page. To track future projections and consensus estimates, the analyst forecast page provides forward-looking expectations.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »